Patterson Companies (PDCO) Q2 2025 earnings summary

Executive summary

• Q2 FY25 net sales rose 1.3% year-over-year to $1.67 billion, with internal sales up 0.6% and Animal Health growth offsetting Dental segment declines.

• GAAP EPS was $0.30 and adjusted EPS $0.47, both impacted by the Change Healthcare cyberattack.

• $96.2 million returned to shareholders via dividends and buybacks in the first six months of FY25.

• The company is evaluating strategic alternatives, including a potential sale, merger, or business combination, to maximize shareholder value.

• Cost management actions, including headcount reductions, are expected to generate $16 million in annual savings.

Financial highlights

• Q2 FY25 gross margin was 19.6% (GAAP) and 20.0% (adjusted), both down year-over-year.

• Q2 net income attributable to the company was $26.8 million ($0.30/share), down from $40.0 million ($0.42/share) last year.

• Adjusted net income for Q2 was $41.8 million ($0.47/share), down from $47.3 million ($0.50/share) year-over-year.

• Free cash flow for the first six months was $12.2 million, up $41.5 million year-over-year.

• Six-month net sales were $3.22 billion, a 0.4% decrease year-over-year; internal sales down 1.1%.

Outlook and guidance

• FY25 GAAP EPS guidance revised to $1.83–$1.93; adjusted EPS guidance to $2.25–$2.35 per diluted share.

• Guidance reflects persistent dental market pressures, cost-saving measures, and continued investment.

• Guidance excludes unplanned share repurchases, future acquisitions, and certain non-recurring items.

• Assumes end market conditions remain consistent with current trends and stable market environment.

• Annual pre-tax savings from recent severance actions are estimated at $16 million, with $10 million expected in FY2025.